00203-5/asset/a0abd16a-3eaa-4d78-990d-ba94939c04c6/main.assets/gr2_lrg.jpg)
glp-1 agonist cardiovascular outcomes Cardiovascular, mortality, and kidney with receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Real-World Evidence for GLP-1 Receptor
Description
The reputation they tend to have as the latest medications approved for weight loss is far from the whole picture
A market can show strong starts while long-term continuation remains fragile
30249-9/asset/ae163e52-907c-4c99-987f-36b369e8996a/main.assets/gr3.gif)
[DOI] [PubMed] [Google Scholar] 898.Pratley R.E., Aroda V.R., Lingvay I., Ludemann J., Andreassen C., Navarria A
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE
10.1210/me.2014-1103 103 RosenstockJ.Aguilar-SalinasC.KleinE.NepalS.ListJ.ChenR.et al
